Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 368

1.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud AI, Dronca RS, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone AM, Zhang J, Kang SP, Ebbinghaus SW, Anderson KM, Gangadhar T.

Clin Cancer Res. 2018 Apr 23. pii: clincanres.2386.2017. doi: 10.1158/1078-0432.CCR-17-2386. [Epub ahead of print]

PMID:
29685882
2.

A First-in-Human Phase 1 Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, Bullock A, Rock E, Elekes A, Lin C, Kostic D, Ohi N, Rasco D, Papadopoulos KP, Patnaik A, Smith L, Cote GM.

Oncologist. 2018 Mar 6. pii: theoncologist.2017-0325. doi: 10.1634/theoncologist.2017-0325. [Epub ahead of print]

PMID:
29511132
3.

Nondystrophic holocord intramedullary lipoma: an uncommon case.

Bansal S, Sahu RN, Patnaik A.

Childs Nerv Syst. 2018 Apr;34(4):591-592. doi: 10.1007/s00381-018-3757-2. Epub 2018 Feb 19. No abstract available.

PMID:
29460061
4.

Neutrophils and anti-cancer immunity: a paradigm shift in cancer immunotherapy.

Sturey R, Patnaik A.

Oncoscience. 2017 Nov 28;4(11-12):164-165. doi: 10.18632/oncoscience.378. eCollection 2017 Nov. No abstract available.

5.

Development of Thrombotic Thrombocytopenic Purpura in Association With the Monoclonal Antibody, Golimumab, Used to Treat Rheumatoid Arthritis, in a Case With Literature Review.

Cepeda J, Liedke C, Patnaik A, Yao Q.

J Clin Rheumatol. 2017 Dec 29. doi: 10.1097/RHU.0000000000000684. [Epub ahead of print] No abstract available.

PMID:
29293116
6.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS.

J Clin Oncol. 2017 Dec 28:JCO2017756270. doi: 10.1200/JCO.2017.75.6270. [Epub ahead of print]

PMID:
29283791
7.

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A.

Invest New Drugs. 2017 Dec 1. doi: 10.1007/s10637-017-0532-2. [Epub ahead of print]

PMID:
29196957
8.

All Fiber-Coupled OH Planar Laser-Induced-Fluorescence (OH-PLIF)-Based Two-Dimensional Thermometry.

Hsu PS, Jiang N, Patnaik AK, Katta V, Roy S, Gord JR.

Appl Spectrosc. 2018 Apr;72(4):604-610. doi: 10.1177/0003702817744519. Epub 2017 Nov 28.

PMID:
29148279
9.

FLEET velocimetry for combustion and flow diagnostics.

DeLuca NJ, Miles RB, Jiang N, Kulatilaka WD, Patnaik AK, Gord JR.

Appl Opt. 2017 Nov 1;56(31):8632-8638. doi: 10.1364/AO.56.008632.

PMID:
29091674
10.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.

11.

Extensive intracranial calcification of pseudo-TORCH syndrome with features of Dandy-Walker malformation.

Patnaik A, Mishra SS, Das S.

Asian J Neurosurg. 2017 Jul-Sep;12(3):541-543. doi: 10.4103/1793-5482.145162.

12.

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.

Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQM.

Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. doi: 10.1158/1078-0432.CCR-17-1243. Epub 2017 Jun 20.

PMID:
28634283
13.

Structure and Dynamics of a N-Methylfulleropyrrolidine-Mediated Gold Nanocomposite: A Spectroscopic Ruler.

Sutradhar S, Patnaik A.

ACS Appl Mater Interfaces. 2017 Jul 5;9(26):21921-21932. doi: 10.1021/acsami.7b02640. Epub 2017 Jun 20.

PMID:
28593769
14.

Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.

Piizzi G, Parker DT, Peng Y, Dobler M, Patnaik A, Wattanasin S, Liu E, Lenoir F, Nunez J, Kerrigan J, McKenney D, Osborne C, Yu D, Lanieri L, Bojkovic J, Dzink-Fox J, Lilly MD, Sprague ER, Lu Y, Wang H, Ranjitkar S, Xie L, Wang B, Glick M, Hamann LG, Tommasi R, Yang X, Dean CR.

J Med Chem. 2017 Jun 22;60(12):5002-5014. doi: 10.1021/acs.jmedchem.7b00377. Epub 2017 Jun 9.

PMID:
28549219
15.

Effect of Selected Yogic Practices on Pain and Disability in Patients with Lumbar Spondylitis.

Manik RK, Mahapatra AK, Gartia R, Bansal S, Patnaik A.

Int J Yoga. 2017 May-Aug;10(2):81-87. doi: 10.4103/0973-6131.205516.

16.

Infective Endocarditis of the Left Main to Right Atrial Coronary Cameral Fistula.

Mishra RC, Barik R, Patnaik AN.

J Cardiovasc Echogr. 2016 Oct-Dec;26(4):123-126. doi: 10.4103/2211-4122.192178.

17.

Intraventricular glioblastoma multiforme mimicking meningioma and review of the literature.

Patnaik A, Mishra SS, Senapati SB.

Asian J Neurosurg. 2017 Jan-Mar;12(1):75-77. doi: 10.4103/1793-5482.145104.

18.

Spontaneous extradural and subgaleal hematoma: A rare neurosurgical crisis of sickle cell disease.

Mishra SS, Senapati SB, Gouda AK, Behera SK, Patnaik A.

Asian J Neurosurg. 2017 Jan-Mar;12(1):47-50. doi: 10.4103/1793-5482.144177.

19.

Unusual Nonemissive Behavior of Rubrene J-Aggregates: A Rare Violation.

Aggarwal N, Patnaik A.

J Phys Chem B. 2017 Apr 13;121(14):3190-3201. doi: 10.1021/acs.jpcb.7b02072. Epub 2017 Mar 30.

PMID:
28334526
20.

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC.

Cancer Discov. 2017 Jul;7(7):750-765. doi: 10.1158/2159-8290.CD-16-0778. Epub 2017 Mar 8.

PMID:
28274958
21.

Regio-selective lipase catalyzed hydrolysis of oxanorbornane-based sugar-like amphiphiles at air-water interface: A polarized FT-IRRAS study.

Sarangi NK, Ganesan M, Muraleedharan KM, Patnaik A.

Chem Phys Lipids. 2017 Apr;204:25-33. doi: 10.1016/j.chemphyslip.2017.02.004. Epub 2017 Feb 22.

PMID:
28235449
22.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.

Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA.

Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.

PMID:
28168303
23.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2.

24.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.

Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17.

PMID:
28097385
25.

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV.

J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21.

26.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

27.

Sensitivity, stability, and precision of quantitative Ns-LIBS-based fuel-air-ratio measurements for methane-air flames at 1-11 bar.

Hsu PS, Gragston M, Wu Y, Zhang Z, Patnaik AK, Kiefer J, Roy S, Gord JR.

Appl Opt. 2016 Oct 1;55(28):8042-8048. doi: 10.1364/AO.55.008042.

PMID:
27828047
28.

Investigation of titania nanoparticles on behaviour and mechanosensory organ of Drosophila melanogaster.

Sabat D, Patnaik A, Ekka B, Dash P, Mishra M.

Physiol Behav. 2016 Dec 1;167:76-85. doi: 10.1016/j.physbeh.2016.08.032. Epub 2016 Sep 5.

PMID:
27609308
29.

Infective endocarditis caused by Stenotrophomonas maltophilia: A report of two cases and review of literature.

Subhani S, Patnaik AN, Barik R, Nemani L.

Indian Heart J. 2016 Sep;68 Suppl 2:S267-S270. doi: 10.1016/j.ihj.2015.07.048. Epub 2016 Jan 14. Review.

30.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators.

Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.

PMID:
27745820
31.

Recurrence of spinal schwannoma: Is it preventable?

Senapati SB, Mishra SS, Dhir MK, Patnaik A, Panigrahi S.

Asian J Neurosurg. 2016 Oct-Dec;11(4):451.

32.

P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy.

Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl N, Aggarwal C, Horn L, Patnaik A, Middleton GW, Gubens M, Hellmann M, Soria JC, Lubiniecki GM, Zhang J, Piperdi B, Garon EB.

J Thorac Oncol. 2016 Oct;11(10S):S241-S242. doi: 10.1016/j.jtho.2016.08.110. Epub 2016 Sep 22. No abstract available.

33.

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.

Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

34.

Nuclear and Chloroplast DNA Variation Provides Insights into Population Structure and Multiple Origin of Native Aromatic Rices of Odisha, India.

Roy PS, Rao GJ, Jena S, Samal R, Patnaik A, Patnaik SS, Jambhulkar NN, Sharma S, Mohapatra T.

PLoS One. 2016 Sep 6;11(9):e0162268. doi: 10.1371/journal.pone.0162268. eCollection 2016.

35.

Differentiation and description of aromatic short grain rice landraces of eastern Indian state of Odisha based on qualitative phenotypic descriptors.

Roy PS, Samal R, Rao GJ, Patnaik SS, Jambhulkar NN, Patnaik A, Mohapatra T.

BMC Ecol. 2016 Aug 9;16:36. doi: 10.1186/s12898-016-0086-8.

36.

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.

Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S.

Cancer Chemother Pharmacol. 2016 Sep;78(3):491-500. doi: 10.1007/s00280-016-3090-y. Epub 2016 Jul 8.

PMID:
27392790
37.

Considerations for double-hand replantation in a resource-constrained healthcare facility.

Nayak BB, Mohanty N, Patnaik AP, Bal PK.

Indian J Plast Surg. 2016 Jan-Apr;49(1):81-5. doi: 10.4103/0970-0358.182233.

38.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

39.

Spontaneous leaking craniopharyngioma causing preoperative chemical meningitis.

Patnaik A, Mahapatra AK, Sarkar S, Samal DK.

Surg Neurol Int. 2016 Apr 14;7:41. doi: 10.4103/2152-7806.180466. eCollection 2016. No abstract available.

40.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
41.

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.

Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Fairbrother WJ, Wong H, Budha N, Darbonne WC, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera CC, Infante JR.

Clin Cancer Res. 2016 Sep 15;22(18):4567-73. doi: 10.1158/1078-0432.CCR-16-0308. Epub 2016 Apr 13.

42.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD.

J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7.

43.

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C.

Clin Cancer Res. 2016 Jul 15;22(14):3672-82. doi: 10.1158/1078-0432.CCR-15-2309. Epub 2016 Mar 2.

44.

Assessment of American College of Rheumatology-Endorsed Quality Indicators in Rheumatoid Arthritis Patients: A Quality Improvement Initiative.

Anderson E, Bajaj P, Raghavan S, Patnaik A, Roppelt H.

J Clin Rheumatol. 2016 Mar;22(2):63-7. doi: 10.1097/RHU.0000000000000323.

PMID:
26906296
45.

Cellulose Buccoadhesive Film Bearing Glimepiride: Physicomechanical Characterization and Biophysics of Buccoadhesion.

Meher JG, Tarai M, Patnaik A, Mishra P, Yadav NP.

AAPS PharmSciTech. 2016 Aug;17(4):940-50. doi: 10.1208/s12249-015-0419-5. Epub 2015 Oct 9.

PMID:
26831445
46.

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

Tolcher AW, Papadopoulos KP, Patnaik A, Wilson K, Thayer S, Zanghi J, Gemo AT, Kavanaugh WM, Keer HN, LoRusso PM.

Ann Oncol. 2016 Mar;27(3):526-32. doi: 10.1093/annonc/mdv591. Epub 2015 Dec 8.

PMID:
26646757
47.

A rare case of giant multiseptated thoracic myelomeningocele with segmental placode.

Patnaik A, Mahapatra AK.

Surg Neurol Int. 2015 Nov 16;6:170. doi: 10.4103/2152-7806.169554. eCollection 2015. No abstract available.

48.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.

49.

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL.

Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21.

50.

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.

Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK.

Clin Cancer Res. 2016 Feb 15;22(4):827-36. doi: 10.1158/1078-0432.CCR-15-0431. Epub 2015 Oct 7.

Supplemental Content

Loading ...
Support Center